ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00243204
Recruitment Status : Terminated (FDA Hold May 2007)
First Posted : October 21, 2005
Last Update Posted : June 8, 2007
Sponsor:
Information provided by:
Point Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Primary Completion Date : No date given
  Study Completion Date : No date given